Understanding Infection, Viral Exacerbation and Respiratory Symptoms at Admission-Longitudinal (UNIVERSAL) study: a prospective observational cohort study protocol DOI Creative Commons
Tommaso Morelli, Martha Purcell, Pedro Rodrigues

et al.

BMJ Open, Journal Year: 2025, Volume and Issue: 15(4), P. e093427 - e093427

Published: April 1, 2025

Background Respiratory viral infections (RVIs) are a significant cause of morbidity and hospital admission worldwide. However, the management most infection-associated diseases remains primarily supportive. The recent COVID-19 pandemic has underscored urgent need for deeper understanding RVIs to improve patient outcomes develop effective treatment strategies. Understanding Infection, Viral Exacerbation Symptoms at Admission-Longitudinal Study is an observational study which addresses this by investigating heterogeneity in hospitalised adults, aiming identify clinical biological predictors adverse outcomes. This aims bridge critical knowledge gaps course economic impact characterising phenotypic diversity these their recovery patterns following thus assisting with optimal design future interventional studies. Methods analysis prospective longitudinal (V.6, 20 September 2023) will be conducted across multiple UK secondary care sites from August 2022 onwards, aim enrol 1000 participants testing positive RVI. Adults admitted respiratory symptoms who test via BioFire® FilmArray® System or other validated diagnostic PCR tests enrolled. data collected include demographics, history, comorbidities experienced prior to, during after hospitalisation follow-up discharge weeks 1, 2, 4, 8, 12 26. In addition, samples time points stay. primary endpoints different disease progression length Secondary healthcare cost. Exploratory focus on biomarker profiles associated virus type Ethics dissemination protocol received ethical approval relevant committees (English Reference Number: 22/WM/0119; Scottish 22-SS-0101, 20/09/2023). For patients lack capacity consent, complies Mental Capacity Act 2005, using consultee process where family member, carer independent clinician may provide assent behalf patient. Data all centres analysed together disseminated through peer-reviewed journals, conference presentations workshops. group ensure that families informed findings promptly accessible format. Trial registration number ISRCTN49183956 .

Language: Английский

Understanding Infection, Viral Exacerbation and Respiratory Symptoms at Admission-Longitudinal (UNIVERSAL) study: a prospective observational cohort study protocol DOI Creative Commons
Tommaso Morelli, Martha Purcell, Pedro Rodrigues

et al.

BMJ Open, Journal Year: 2025, Volume and Issue: 15(4), P. e093427 - e093427

Published: April 1, 2025

Background Respiratory viral infections (RVIs) are a significant cause of morbidity and hospital admission worldwide. However, the management most infection-associated diseases remains primarily supportive. The recent COVID-19 pandemic has underscored urgent need for deeper understanding RVIs to improve patient outcomes develop effective treatment strategies. Understanding Infection, Viral Exacerbation Symptoms at Admission-Longitudinal Study is an observational study which addresses this by investigating heterogeneity in hospitalised adults, aiming identify clinical biological predictors adverse outcomes. This aims bridge critical knowledge gaps course economic impact characterising phenotypic diversity these their recovery patterns following thus assisting with optimal design future interventional studies. Methods analysis prospective longitudinal (V.6, 20 September 2023) will be conducted across multiple UK secondary care sites from August 2022 onwards, aim enrol 1000 participants testing positive RVI. Adults admitted respiratory symptoms who test via BioFire® FilmArray® System or other validated diagnostic PCR tests enrolled. data collected include demographics, history, comorbidities experienced prior to, during after hospitalisation follow-up discharge weeks 1, 2, 4, 8, 12 26. In addition, samples time points stay. primary endpoints different disease progression length Secondary healthcare cost. Exploratory focus on biomarker profiles associated virus type Ethics dissemination protocol received ethical approval relevant committees (English Reference Number: 22/WM/0119; Scottish 22-SS-0101, 20/09/2023). For patients lack capacity consent, complies Mental Capacity Act 2005, using consultee process where family member, carer independent clinician may provide assent behalf patient. Data all centres analysed together disseminated through peer-reviewed journals, conference presentations workshops. group ensure that families informed findings promptly accessible format. Trial registration number ISRCTN49183956 .

Language: Английский

Citations

0